Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1967 1
1968 6
1969 4
1970 6
1971 4
1972 8
1973 7
1974 8
1975 5
1976 16
1977 17
1978 16
1979 24
1980 29
1981 24
1982 25
1983 40
1984 32
1985 27
1986 48
1987 37
1988 44
1989 37
1990 44
1991 43
1992 39
1993 35
1994 33
1995 41
1996 34
1997 35
1998 34
1999 33
2000 26
2001 28
2002 19
2003 26
2004 23
2005 22
2006 24
2007 26
2008 29
2009 27
2010 22
2011 23
2012 27
2013 29
2014 28
2015 25
2016 29
2017 31
2018 19
2019 18
2020 32
2021 36
2022 45
2023 42
2024 38
2025 39
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,496 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Efficacy and Safety of 8 Atropine Concentrations for Myopia Control in Children: A Network Meta-Analysis.
Ha A, Kim SJ, Shim SR, Kim YK, Jung JH. Ha A, et al. Ophthalmology. 2022 Mar;129(3):322-333. doi: 10.1016/j.ophtha.2021.10.016. Epub 2021 Oct 22. Ophthalmology. 2022. PMID: 34688698 Free article. Review.
TOPIC: Comparative efficacy and safety of different concentrations of atropine for myopia control. CLINICAL RELEVANCE: Atropine is known to be an effective intervention to delay myopia progression. ...We selected studies involving atropine treatment of at lea …
TOPIC: Comparative efficacy and safety of different concentrations of atropine for myopia control. CLINICAL RELEVANCE: Atropine …
Effect of Low-Concentration Atropine Eyedrops vs Placebo on Myopia Incidence in Children: The LAMP2 Randomized Clinical Trial.
Yam JC, Zhang XJ, Zhang Y, Yip BHK, Tang F, Wong ES, Bui CHT, Kam KW, Ng MPH, Ko ST, Yip WWK, Young AL, Tham CC, Chen LJ, Pang CP. Yam JC, et al. JAMA. 2023 Feb 14;329(6):472-481. doi: 10.1001/jama.2022.24162. JAMA. 2023. PMID: 36786791 Free PMC article. Clinical Trial.
INTERVENTIONS: Participants were assigned at random to the 0.05% atropine (n = 160), 0.01% atropine (n = 159), and placebo (n = 155) groups and had eyedrops applied once nightly in both eyes over 2 years. ...Photophobia was the most common adverse event and was repo …
INTERVENTIONS: Participants were assigned at random to the 0.05% atropine (n = 160), 0.01% atropine (n = 159), and placebo (n …
Efficacy of atropine, orthokeratology, and combined atropine with orthokeratology for childhood myopia: A systematic review and network meta-analysis.
Tsai HR, Wang JH, Huang HK, Chen TL, Chen PW, Chiu CJ. Tsai HR, et al. J Formos Med Assoc. 2022 Dec;121(12):2490-2500. doi: 10.1016/j.jfma.2022.05.005. Epub 2022 Jun 7. J Formos Med Assoc. 2022. PMID: 35688780 Free article.
For refractive change, SUCRA analysis revealed that the hierarchy was high-dose (0.5%-1%), moderate-dose (0.1%-0.25%), and low-dose (0.01%-0.05%) atropine. Regarding AL, SUCRA analysis revealed the following hierarchy: Ortho-K combined with 0.01% atropine, high-dose …
For refractive change, SUCRA analysis revealed that the hierarchy was high-dose (0.5%-1%), moderate-dose (0.1%-0.25%), and low-dose (0.01%-0 …
0.01% Atropine Eye Drops in Children With Myopia and Intermittent Exotropia: The AMIXT Randomized Clinical Trial.
Wang Z, Li T, Zuo X, Zhang T, Liu L, Zhou C, Leng Z, Chen X, Wang L, Wang X, Liu H. Wang Z, et al. JAMA Ophthalmol. 2024 Aug 1;142(8):722-730. doi: 10.1001/jamaophthalmol.2024.2295. JAMA Ophthalmol. 2024. PMID: 38958962 Free PMC article. Clinical Trial.
However, evidence is limited regarding atropine interventions for myopia control in children with myopia and intermittent exotropia (IXT). OBJECTIVE: To evaluate the efficacy and safety of 0.01% atropine eye drops on myopia progression, exotropia conditions, and bin …
However, evidence is limited regarding atropine interventions for myopia control in children with myopia and intermittent exotropia ( …
Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2).
Chia A, Chua WH, Cheung YB, Wong WL, Lingham A, Fong A, Tan D. Chia A, et al. Ophthalmology. 2012 Feb;119(2):347-54. doi: 10.1016/j.ophtha.2011.07.031. Epub 2011 Oct 2. Ophthalmology. 2012. PMID: 21963266 Clinical Trial.
PURPOSE: Our previous study, Atropine for the Treatment of Myopia 1 (ATOM1), showed that atropine 1% eyedrops were effective in controlling myopic progression but with visual side effects resulting from cycloplegia and mydriasis. ...Allergic conjunctivitis and derma …
PURPOSE: Our previous study, Atropine for the Treatment of Myopia 1 (ATOM1), showed that atropine 1% eyedrops were effective i …
Two-Year Clinical Trial of the Low-Concentration Atropine for Myopia Progression (LAMP) Study: Phase 2 Report.
Yam JC, Li FF, Zhang X, Tang SM, Yip BHK, Kam KW, Ko ST, Young AL, Tham CC, Chen LJ, Pang CP. Yam JC, et al. Ophthalmology. 2020 Jul;127(7):910-919. doi: 10.1016/j.ophtha.2019.12.011. Epub 2019 Dec 21. Ophthalmology. 2020. PMID: 32019700 Clinical Trial.
Compared with the first year, the second-year efficacy of 0.05% and 0.025% atropine remained similar (P >0.1), but improved mildly in the 0.01% atropine group (P = 0.04). ...CONCLUSIONS: Over 2 years, the efficacy of 0.05% atropine observed was double that …
Compared with the first year, the second-year efficacy of 0.05% and 0.025% atropine remained similar (P >0.1), but improved mildly …
Atropine Treatment for Hypertrophic Pyloric Stenosis: A Systematic Review and Meta-Analysis.
Lauriti G, Cascini V, Chiesa PL, Pierro A, Zani A. Lauriti G, et al. Eur J Pediatr Surg. 2018 Oct;28(5):393-399. doi: 10.1055/s-0037-1604116. Epub 2017 Jul 12. Eur J Pediatr Surg. 2018. PMID: 28701002
Our aims were to review the efficacy of atropine in treating HPS and to compare atropine therapy versus pyloromyotomy. MATERIALS AND METHODS: Using a defined search strategy (PubMed, MEDLINE, OVID, Embase, Cochrane databases), two investigators independently identif …
Our aims were to review the efficacy of atropine in treating HPS and to compare atropine therapy versus pyloromyotomy. MATERIA …
Atropine for the treatment of childhood myopia.
Chua WH, Balakrishnan V, Chan YH, Tong L, Ling Y, Quah BL, Tan D. Chua WH, et al. Ophthalmology. 2006 Dec;113(12):2285-91. doi: 10.1016/j.ophtha.2006.05.062. Epub 2006 Sep 25. Ophthalmology. 2006. PMID: 16996612 Clinical Trial.
PURPOSE: To evaluate the efficacy and safety of topical atropine, a nonselective muscarinic antagonist, in slowing the progression of myopia and ocular axial elongation in Asian children. ...The differences in myopia progression and axial elongation between the 2 groups we …
PURPOSE: To evaluate the efficacy and safety of topical atropine, a nonselective muscarinic antagonist, in slowing the progression of …
Five-Year Clinical Trial of the Low-Concentration Atropine for Myopia Progression (LAMP) Study: Phase 4 Report.
Zhang XJ, Zhang Y, Yip BHK, Kam KW, Tang F, Ling X, Ng MPH, Young AL, Wu PC, Tham CC, Chen LJ, Pang CP, Yam JC. Zhang XJ, et al. Ophthalmology. 2024 Sep;131(9):1011-1020. doi: 10.1016/j.ophtha.2024.03.013. Epub 2024 Mar 16. Ophthalmology. 2024. PMID: 38494130 Clinical Trial.
PURPOSE: To evaluate (1) the long-term efficacy of low-concentration atropine over 5 years, (2) the proportion of children requiring re-treatment and associated factors, and (3) the efficacy of pro re nata (PRN) re-treatment using 0.05% atropine from years 3 to 5. . …
PURPOSE: To evaluate (1) the long-term efficacy of low-concentration atropine over 5 years, (2) the proportion of children requiring …
Effect of atropine, orthokeratology and combined treatments for myopia control: a 2-year stratified randomised clinical trial.
Xu S, Li Z, Zhao W, Zheng B, Jiang J, Ye G, Feng Z, Long W, He L, He M, Hu Y, Yang X. Xu S, et al. Br J Ophthalmol. 2023 Nov 22;107(12):1812-1817. doi: 10.1136/bjo-2022-321272. Br J Ophthalmol. 2023. PMID: 36229177 Clinical Trial.
PURPOSE: To investigate the 2-year efficacy of atropine, orthokeratology (ortho-k) and combined treatment on myopia. To explore the factors influencing the efficacy. ...CONCLUSIONS: Atropine combined with ortho-k treatment can improve the efficacy of myopia control …
PURPOSE: To investigate the 2-year efficacy of atropine, orthokeratology (ortho-k) and combined treatment on myopia. To explore the f …
1,496 results